Evidence map›Paper›PMID 35519075›Full record

ArticleRSC advances2020

Poly(3-hydroxybutyrate)/poly(amine)-coated nickel oxide nanoparticles for norfloxacin delivery: antibacterial and cytotoxicity efficiency.

Nehal Salahuddin, Mohamed Gaber, Maie Mousa, Mohamed A Abdelwahab

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Lipid Microspheres for Topical Delivery of Norfloxacin: Development and Evaluation.Recent advances in drug delivery and formulation · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nehal SalahuddinChemistry Department, Faculty of Science, Tanta University Tanta 31527 Egypt nehal.attaf@science.tanta.edu.eg mohamed.abdelwahab@science.tanta.edu.eg.ORCID https://orcid.org/0000-0002-8501-3681
Mohamed GaberChemistry Department, Faculty of Science, Tanta University Tanta 31527 Egypt nehal.attaf@science.tanta.edu.eg mohamed.abdelwahab@science.tanta.edu.eg.
Maie MousaChemistry Department, Faculty of Science, Tanta University Tanta 31527 Egypt nehal.attaf@science.tanta.edu.eg mohamed.abdelwahab@science.tanta.edu.eg.
Mohamed A AbdelwahabChemistry Department, Faculty of Science, Tanta University Tanta 31527 Egypt nehal.attaf@science.tanta.edu.eg mohamed.abdelwahab@science.tanta.edu.eg.ORCID https://orcid.org/0000-0002-8094-3644
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sustained release dosage forms enable prolonged and continuous release of a drug in the gastrointestinal tract for medication characterized by a short half lifetime. In this study, the effect of blending polyamine on poly(3-hydroxybutyrate) (PHB) as a carrier for norfloxacin (NF) was studied. The prepared blend was mixed with different amounts of NiO nanoparticles and characterized using FTIR analysis, X-ray diffraction analysis, thermogravimetric analysis, dynamic light scattering, transmission electron microscopy and scanning electron microscopy. It was found that the drug released from the nanocomposite has a slow rate in comparison with NiO, PHB, and PHB/polyamine blend. The highest ratio of NiO content to the matrix (highest NF loading), leads to a slower rate of drug release. The release from the nanocomposites showed a faster rate at pH = 2 than that at pH = 7.4. The mechanisms of NF adsorption and release were studied on PHB/polyamine-3% NiO nanocomposite. In addition, the antimicrobial efficacy of nanocomposites loaded with the drug was determined and compared with the free drug. Inclusion of NiO into PHB/polyamine showed a higher efficacy against

Identifiers

PMID35519075
PMCPMC9056780
OpenAlexW3085773425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.